Dupilumab: An emerging therapy in allergic fungal rhinosinusitis.
World Allergy Organ J
; 15(3): 100638, 2022 Mar.
Article
in En
| MEDLINE
| ID: mdl-35497650
ABSTRACT
Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). This case series reports 4 patients with resistant AFRS concomitant with asthma, for which dupilumab therapy was administered. Long-term follow-ups showed that dupilumab improved the symptoms and improved the results of objective tools such as imaging and pulmonary function test.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
World Allergy Organ J
Year:
2022
Document type:
Article
Affiliation country:
Saudi Arabia